Oculis launches PIONEER registrational trials for Privosegtor in optic neuritis
OCS•Oculis launched two registrational PIONEER trials of Privosegtor for optic neuritis following positive Phase 2 ACUITY results.
1. Trials launched
Oculis launched two registrational trials in its PIONEER clinical program for optic neuritis, following positive Phase 2 ACUITY results. The company is also advancing Privosegtor toward an IND filing in the fourth quarter for acute multiple sclerosis relapses, supported by FDA pre-IND feedback.
